Gyre Therapeutics, Inc. GYRE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $22.52M+2.1% | $37.2M+33.4% | $30.56M+19.9% | $26.77M+6.1% | $22.06M-18.8% | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Other Nonoperating Income Expense by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0-100% | |
| Gyre | $191K+324% | -$387K-93.5% | $217K+406% | $92K+174% | $45K-25.0% | |
| Gyre Pharmaceuticals | -$162K-361% | -$1.81M-25.5% | $510K+12,850% | -$237K-547% | $62K0.0% | |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest by Business | ||||||
| All Other Segments | -$6K-100% | -$3K— | -$11K-120% | -$2K-100% | -$3K— | |
| Gyre | -$6M-816% | -$2.54M— | -$1.74M+17.8% | -$1.75M-207% | $838K-72.4% | |
| Gyre Pharmaceuticals | -$3.85M-233% | $1.18M-38.6% | $7.69M+54.5% | $3.33M+14.8% | $2.9M-58.0% | |
| Operating Income by Business | ||||||
| All Other Segments | -$6K-100% | -$3K— | -$11K-120% | -$2K-100% | -$3K— | |
| Gyre | -$6.28M-330% | -$3.04M-92.8% | -$1.93M-6.3% | -$2.06M-78.6% | -$1.46M-11.3% | |
| Gyre Pharmaceuticals | -$3.07M-182% | $3.16M+41.2% | $8.87M+46.5% | $4.23M-2.7% | $3.74M-60.2% | |
| Operating Expenses by Business | ||||||
| All Other Segments | $6K+100% | $3K— | $11K+120% | $2K+100% | $3K— | |
| Gyre | $6.28M+330% | $3.04M+92.8% | $1.93M+6.3% | $2.06M+78.6% | $1.46M+11.3% | |
| Gyre Pharmaceuticals | $25.59M+39.7% | $37.71M+33.1% | $20.07M+8.6% | $21.39M+6.4% | $18.32M+9.0% | |
| Income Tax Expense Benefit by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | $0— | —— | $2K+300% | —— | $0-100% | |
| Gyre Pharmaceuticals | $621K-31.1% | $1.3M+547% | $1.69M+57.4% | $662K-55.8% | $901K-64.6% | |
| Cost of Goods Sold by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $1.23M+37.2% | $1.74M+48.1% | $1.63M+69.9% | $1.15M+49.5% | $894K-8.7% | |
| Total Assets by Business | ||||||
| All Other Segments | $357K-2.2% | $356K-3.3% | $357K-60.9% | $365K-60.0% | $365K-60.0% | |
| Gyre | $24.31M+244% | $27.37M+154% | $29M+172% | $31.14M+196% | $7.07M-39.8% | |
| Gyre Pharmaceuticals | $137.35M+12.3% | $138.41M+21.1% | $130.03M+14.4% | $121.14M+10.6% | $122.35M+11.9% | |
| Transaction Costs by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | —— | |
| Gyre Pharmaceuticals | $0— | —— | —— | —— | —— | |
| Gyre | $2.55M— | —— | —— | —— | —— | |
| Selling And Marketing Expense by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $14.14M+30.4% | $23.82M+41.3% | $15.33M+11.9% | $15.19M+5.4% | $10.84M-13.6% | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Research And Development Expense Excluding Acquired In Process Cost by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $5.47M+80.5% | $3.99M+11.3% | $2.15M-15.9% | $3.34M+8.4% | $3.03M+50.8% | |
| Gyre | $1.27M+1,827% | $824K+549% | $217K-2.3% | $88K-68.3% | $66K-61.8% | |
| General And Administrative Expense by Business | ||||||
| All Other Segments | $6K+100% | $3K— | $11K+120% | $2K+100% | $3K— | |
| Gyre | $2.46M+76.0% | $2.21M+52.8% | $1.71M+7.5% | $1.97M+125% | $1.4M+22.3% | |
| Gyre Pharmaceuticals | $4.76M+33.8% | $4.49M+11.6% | $2.6M+16.6% | $2.86M+12.1% | $3.56M+57.6% | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $178K+45.9% | $144K— | $668K-3.6% | $256K-82.4% | $122K-43.8% | |
| Gyre | $0— | —— | —— | —— | $0-100% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | $870K+103% | $815K+43.7% | $808K+241% | $557K+3,381% | $429K+3,800% | |
| Gyre Pharmaceuticals | $1.71M+2,096% | $3.78M— | $339K— | $349K— | $78K— | |
| Fair Value Adjustment Of Warrants by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre | -$89K+96.1% | -$263K-35.6% | $23K-89.9% | -$212K+92.7% | -$2.26M+47.4% | |
| Gyre Pharmaceuticals | $0— | —— | —— | —— | $0— | |
| Revenue (Gross) by Product | ||||||
| Contiva | $849+204% | $2.5M— | $1.25M— | $1.78M— | $279— | |
| Etorel | $672— | $1.48M— | $1.54M— | —— | —— | |
| Other Product | $31-57.5% | —— | $81K-60.1% | —— | $73— | |
| Concentration Risk % by Product | ||||||
| Contiva | 3.8%+2.5pp | 0.9%— | 4.1%— | 5.6%— | 1.3%— | |
| Etorel | 3%— | —— | 5.1%— | 6%— | 0%— | |
| Other Product | 0.1%-0.2pp | —— | 0.2%-0.6pp | —— | 0.3%— | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 700.0% | 70— | 70— | 70— | 70— | |
| Shanghai | 2240.0% | 224— | 224— | 224— | 224— | |
| Zhengzhou | 1800.0% | 180— | 180— | 180— | 180— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
